title: Developmental and pediatric pharmacogenomics.
abstract: Children, as well as adults, should benefit from the discoveries of the genomic era. Many diseases with complex etiologies originate during childhood (e.g., asthma, autism, attention deficit/hyperactivity disorder, epilepsy and juvenile rheumatoid arthritis) and persist into adulthood. Attempts to better understand the genetic basis of age-specific disease processes requires an appreciation that the period of human development encompasses the prenatal period through adolescence, and is a rapidly changing, dynamic process. As a result, pharmacologic modulation of developing gene networks may have unintended and unanticipated consequences that do not become apparent or relevant until later in life. Thus, there is considerable potential for large-scale pharmacogenomic technologies to impact the development and utilization of new therapeutic strategies in children.
authors.affiliation: Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children's Mercy Hospital and Clinics, Kansas City, MO, USA. sleeder@cmh.edu
authors.forename: J Steven
authors.initials: JS
authors.lastname: Leeder
mesh_terms: D002648:Child; D016503:Drug Delivery Systems; D015195:Drug Design; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D010372:Pediatrics / Q000639:trends*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods / Q000639:trends*; D011247:Pregnancy; D013678:Technology, Pharmaceutical
chemical_list: D004364:Pharmaceutical Preparations